✦ LIBER ✦

A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia

✍ Scribed by Joseph D. Borsi; Peter Johan Moe

Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 698 KB
Volume: 60
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19870701)60:1<5::aid-cncr2820600103>3.0.co;2-d

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of doxorubicin in child

Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: Multi-institutional collaborative study

✍ Frost, B.-M. ;Eksborg, S. ;Björk, O. ;Abrahamsson, J. ;Behrendtz, M. ;Castor, A. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

## Abstract ## Background In adults, it has been shown that the pharmacokinetics of doxorubicin are highly variable, despite standardization of the dose based on body surface area (BSA). The purpose of this study was to determine the plasma concentrations of doxorubicin and its active metabolite d

Randomized comparison of moderate-dose m

Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group study

✍ Lange, Beverly J.; Blatt, Julie; Sather, Harland N.; Meadows, Anna T. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

Methotrexate (MTX) infusions of 500-1,000 mg/m2 over 24 hours may improve survival and prevent relapse in children with acute lymphoblastic leukemia (ALL). Childrens Cancer Group (CCG) Study 139 compared weekly oral methotrexate 20 mg/m2/ week (oral MTX) to MTX 500 mg/m2 infused over 24 hours (IV MT

A prospective cohort study determining t

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase : Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study

✍ Lesley G. Mitchell;; the PARKAA Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND Thrombotic events (TEs) are serious secondary complications in children with acute lymphoblastic leukemia (ALL) who receive L‐asparaginase (ASP) therapy; however, the prevalence of TEs has not been established. The primary objective of the Prophylactic Antithrombin Replac